The following scientific exhibits feature Volpara technology:
The impact of mammographic quality control on breast density was studied by Norwegian researchers in the presentation, “Error in recorded compressed breast thickness measurement impacts on volumetric density classification,” (B-1119). Researchers conclude that good mammographic QC is important to acquire accurate breast density results.
“Comparison of subjective breast density categorisation vs VOLPARA software” (C-2275); Researchers from University College Dublin assessed the agreement between US and UK radiologists in visual assessment of density and compared to VolapraDensity. Overall there was a higher agreement between Volpara and US radiologists than UK radiologists indicative of Volpara being trained to match US radiologists.
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“Measuring mammographic density: Comparing a fully automated volumetric assessment versus European radiologists' qualitative classification” (C-0383); Examinations from the Malmo Breast Tomo Screening Trial were used for a reader study comparing visual assessment of breast density with Volpara. The researchers propose adjusting the Volpara thresholds for European populations may improve agreement.
“The results of the IGR study, demonstrating the ability of VolparaDensity to monitor temporal changes in breast density, add to the growing portfolio of scientific evidence supporting the ability of volumetric breast density to improve breast screening,” said Ralph Highnam, Ph.D., CEO and Chief Scientist of Volpara Solutions. “We are proud that this year’s ECR programme also features several studies demonstrating that VolparaAnalytics is an integral component to the standardization of mammographic compression and positioning. This has tremendous opportunity to improve quality control in mammography and patient experience by eliminating technical variability.”
Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is in use at breast imaging centers worldwide to help radiologists objectively assess density from digital mammography and tomosynthesis images to determine which women might benefit from additional imaging. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the 4th and 5th Editions of the BI-RADS Atlas from the ACR. Volpara Solutions technology is currently in use in 33 countries, and more than 7 million women have had their breast density analyzed using VolparaDensity.
About Volpara Solutions
Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand (formerly Matakina Technology). CE-marked and cleared by the FDA, Health Canada, and the TGA, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient-specific x-ray dose, breast compression, breast positioning, and other factors designed to provide critical insight for breast imaging workflow. For more information, visithttp://www.volparasolutions.com.
Back to HCB News
